The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities include oral GLP-1 agonists, next-generation incretin drugs, and convenient non-injectable options for obesity management.

Pomerantz LLP announced investigations into potential securities fraud at AstraZeneca following the failure of its Phase-3 CARDIO-Transform trial for Wainua treatment, which caused the stock to drop 5.7%. The firm is also investigating claims against Alibaba Group and Franklin Covey Co.

AstraZeneca's stock plummeted 5.7% after its Phase 3 CARDIO-TTRansform trial for heart drug Wainua failed to meet its primary endpoint, erasing $24 billion in market value. However, analysts argue the selloff is an overcorrection, as the failed program represents only ~2% of the company's net present value. The fundamental business remains intact with strong margins, existing drug approvals unchanged, and the $80 billion 2030 revenue target untouched. The market punished the company more for a credibility crack than actual financial damage.

Despite expanding biologic adoption and evolving treatment strategies for systemic lupus erythematosus (SLE), research from Spherix Global Insights reveals substantial unmet need remains. While rheumatologists are advancing treatment strategies and increasing biologic utilization, nearly 80% of patients report moderate-to-severe disease with persistent symptoms and frequent flares. Approximately one-third of biologic-treated patients achieve only partial disease control. Recent approvals like Saphnelo® (anifrolumab) and anticipated approvals like Gazyva® (obinutuzumab) for non-renal SLE are expected to expand treatment options.

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

The acute kidney injury (AKI) therapeutic pipeline is experiencing robust growth with 20+ pharmaceutical companies developing 25+ pipeline drugs across various clinical stages. Key players including AstraZeneca, Arch Biopartners, Akebia Therapeutics, and others are advancing promising therapies with diverse mechanisms of action. Recent developments include Phase I initiation of AKB-9090, Phase II trial preparations for LSALT peptide, and anticipated Phase III data from AstraZeneca's ARTEMIS trial in H2 2026.

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

AstraZeneca received FDA approval for Truqap (capivasertib) in combination with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer, marking the first targeted treatment for this patient population. The Phase III CAPItello-281 trial showed a 19% reduction in disease progression or death risk and a 7.5-month improvement in median radiographic progression-free survival. Additionally, Ultomiris received Priority Review for immunoglobulin A nephropathy treatment, with Phase 3 data showing a 46.6% reduction in proteinuria compared to 5.6% for placebo.

AstraZeneca is advancing its oral GLP-1 receptor agonist elecoglipron into Phase 3 trials after demonstrating significant results in Phase 2b studies. The VISTA trial showed 10.5% weight reduction at 26 weeks, while the SOLSTICE trial achieved 1.9% HbA1c reduction in Type 2 diabetes patients. The drug showed a favorable safety profile with mild gastrointestinal side effects.